MRVI

Maravai LifeSciences Holdings, Inc.

$7.86

-2.00%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.

Source: Yahoo Finance
AI summary

Price & performance

1M+2.0%
3M+15.7%
YTD+129.7%
1Y+148.7%
52-week range—
Beta1.33
Full chart and returns against a benchmark

Q-Score

50/ 100

Quality against peers; 50 is the peer median.

Growth46
Risk51
Performance57
Valuation49
Profitability46
Leverage49
Sentiment49
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$185.7M-28.3%
Net income-$130.8M
Net margin-70.4%-14.5 pts
Historical fundamentals

Red flags in filings

2active red flags
Restated financialsMar 18, 2025
Auditor changeJul 18, 2025
Filings, findings and the timeline

Revenue exposure

40%of revenue from outside the US
North America61%
Asia Pacific22%
EMEA17%
Regions, segments, customers and suppliers

Valuation

MRVIIndustryP/E—89.69P/S9.5911.88EV/EBITDA—67.10P/B10.436.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$-0.06
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate